{"product_id":"emibetuzumab-elisa-kit","title":"Emibetuzumab ELISA Kit","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:96T\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplications\u003c\/b\u003e:ELISA\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:P08581\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStability and Storage\u003c\/b\u003e:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDetection method\u003c\/b\u003e:Colorimetric\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSample type\u003c\/b\u003e:Plasma, Serum\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAssay type\u003c\/b\u003e:Quantitative\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSensitivity\u003c\/b\u003e:0.156 μg\/ml\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRange\u003c\/b\u003e:0.31-5 μg\/mL\u003c\/p\u003e\u003cp\u003e\u003cb\u003eRecovery\u003c\/b\u003e:80-120%\u003c\/p\u003e\u003cp\u003e\u003cb\u003eProperties\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExperimental Procedure\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Emibetuzumab (as known as LY2875358) is a humanized immunoglobulin G4 monoclonal bivalent anti-MET antibody that blocks MET signaling. This drug was developed by Eli Lilly \u0026amp; Company and has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. In preclinical models, emibetuzumab inhibited growth of tumors that are dependent on MET, including tumors that exhibit HGF-dependent and HGF-independent biology. Administration of a single dose of emibetuzumab resulted in continuous reduction of MET protein expression for 14 days in mouse xenografts. Emibetuzumab demonstrated dose-dependent, single-agent activity in various MET-expressing tumor models, and additive effects were observed in combination with erlotinib for reducing tumor volume in lung cancer mouse xenograft models. In Phase 1 dose escalation studies, emibetuzumab monotherapy was well tolerated in patients with advanced solid tumors, including gastric cancer, with no dose-limiting toxicities.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAlternative Names\u003c\/b\u003e:LA480, LY-2875358, 1365287-97-3\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:2-8 ℃\u003c\/p\u003e\u003cp\u003e\u003cb\u003eNote\u003c\/b\u003e:For Research Use Only.\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48655942647908,"sku":"DY196018","price":764.95,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_6f3cc09c-85c4-49e4-8566-056081520e4c.jpg?v=1782808784","url":"https:\/\/www.genebiosystems.com\/en-fr\/products\/emibetuzumab-elisa-kit","provider":"GeneBio ","version":"1.0","type":"link"}